Details of Disease

General Information of Disease (ID: DISCVPML)

Disease Name	Gastroesophageal junction adenocarcinoma
Synonyms	esophagogastric adenocarcinoma; gastroesophageal junction adenocarcinoma; esophagogastric junction adenocarcinoma; adenocarcinoma of the gastroesophageal junction; adenocarcinoma of the esophagogastric junction; adenocarcinoma of the cardioesophageal junction; adenocarcinoma of the GE junction; adenocarcinoma of the EG junction; adenocarcinoma of gastroesophageal junction; adenocarcinoma of cardioesophageal junction; adenocarcinoma - GEJ
Disease Class	2B71: Oesophagogastric junction cancer
Definition	A carcinoma that arises from glandular epithelial cells of the esophagogastric junction.
Disease Hierarchy	DIS3IHTY: Adenocarcinoma DISFC6MM: Digestive system carcinoma DISCVPML: Gastroesophageal junction adenocarcinoma
ICD Code	ICD-11 ICD-11: 2B71
Disease Identifiers	MONDO ID MONDO_0003219 UMLS CUI C1332166 MedGen ID 231030

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 5 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Carboplatin	DMG281S	Approved	Small molecular drug	[1]
Cisplatin	DMRHGI9	Approved	Small molecular drug	[2]
Fluorouracil	DMUM7HZ	Approved	Small molecular drug	[3]
Lapatinib	DM3BH1Y	Approved	Small molecular drug	[4]
Paclitaxel	DMLB81S	Approved	Small molecular drug	[5]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
A168	DMJW3F4	Phase 1	Monoclonal antibody	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 4 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
GUCY2C	TTLDPRG	Strong	Altered Expression	[7]
IKZF3	TTCZVFZ	Strong	Genetic Variation	[8]
PLN	TTMCVJF	Strong	Biomarker	[9]
TNS4	TT1K65C	Strong	Altered Expression	[10]
------------------------------------------------------------------------------------

This Disease Is Related to 1 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
MTA3	OTIA6C79	Strong	Altered Expression	[11]
------------------------------------------------------------------------------------

References

1	Carboplatin FDA Label
2	Cisplatin FDA Label
3	Fluorouracil FDA Label
4	Lapatinib FDA Label
5	Paclitaxel FDA Label
6	Clinical pipeline report, company report or official report of Klus Pharma
7	TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study.Cancer Res Treat. 2018 Apr;50(2):398-404. doi: 10.4143/crt.2017.074. Epub 2017 May 10.
8	Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.JAMA Oncol. 2017 Sep 1;3(9):1237-1244. doi: 10.1001/jamaoncol.2017.0515.
9	The prognostic relevance of parapyloric lymph node metastasis in Siewert type II/III adenocarcinoma of the esophagogastric junction.Eur J Surg Oncol. 2017 Dec;43(12):2333-2340. doi: 10.1016/j.ejso.2017.08.017. Epub 2017 Sep 8.
10	Correction: Overexpression of CTEN relates to tumor malignant potential and poor outcomes of adenocarcinoma of the esophagogastric junction.Oncotarget. 2019 Oct 1;10(55):5726. doi: 10.18632/oncotarget.27229. eCollection 2019 Oct 1.
11	The metastasis-associated gene MTA3, a component of the Mi-2/NuRD transcriptional repression complex, predicts prognosis of gastroesophageal junction adenocarcinoma.PLoS One. 2013 May 3;8(5):e62986. doi: 10.1371/journal.pone.0062986. Print 2013.